Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4α, and constitutive androstane receptor with docetaxel pharmacokinetics

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7126-7132

  Tham, Lai San ^a,d   Holford, Nicholas H G ^c   Hor, Sok Ying ^b   Tan, Theresa ^b   Wang, Lingzhi ^a   Lim, Rui Chen ^a   Lee, How Sung ^b   Lee, Soo Chin ^a   Goh, Boon Cher ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 3A; DOCETAXEL; DOXORUBICIN; HEPATIC NUCLEAR FACTOR 4ALPHA; NUCLEAR FACTOR; OROSOMUCOID; PREGNANE X RECEPTOR; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; ARTICLE; ASIA; BODY HEIGHT; BODY SIZE; BODY SURFACE; BODY WEIGHT; BREAST CANCER; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; LIQUID CHROMATOGRAPHY; LIVER FUNCTION; MAJOR CLINICAL STUDY; NONLINEAR SYSTEM; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POPULATION GENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; TAXOIDS; TRANSCRIPTION FACTORS;

EID: 37249063061     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1276     Document Type: Article

References (28)

1. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-91.
2. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
3. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
4. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96.
5. Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001;19:163-9.
6. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6:1255-8.
7. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-90.
8. Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004;40:1170-8.
9. Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005;77:43-53.
10. ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23:1070-7.
11. Rivory LP, Slaviero K, Seale JP, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000;6:3480-5.
12. Puisset F, Chatelut E, Dalenc F, et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004;54:265-72.
13. Yamamoto N, Tamura T, Murakami H, et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005;23:1061-9.
14. Baker SD, van Schaik RH, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004;10:8341-50.
15. Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005;11:7398-404.
16. Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001;33:668-75.
17. Bort R, Gomez-Lechon MJ, Castell JV, Jover R. Role of hepatocyte nuclear factor 3γ in the expression of human CYP2C genes. Arch Biochem Biophys 2004;426:63-72.
18. Chen Y, Kissling G, Negishi M, Goldstein JA. The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4α to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther 2005;314:1125-33.
19. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci US A1998;95:12208-13.
20. Quattrochi LC, Guzelian PS. Cyp3A regulation: from pharmacology to nuclear receptors. Drug Metab Dispos 2001;29:615-22.
21. Hor SY, Lee SC, Wong CI, et al. PXR, CAR, and HNF-4a genotype and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian Patients. Pharmacogenom J. Epub 2007 Sep 18.
22. Wang LZ, Goh BC, Grigg ME, et al. A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. Rapid Commun Mass Spectrom 2003;17:1548-52.
23. Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005;11:8097-104.
24. Wei P, Zhang J, Dowhan DH, Han Y, Moore DD. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenom J 2002;2:117-26.
25. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996;24:153-72.
26. 14 radiolabelled taxotere (TXT) (RP56976, NSC628503) in cancer patients. Proc Am Assoc Cancer Res 1993;34:2221.
27. Slaviero KA, Clarke SJ, McLachlan AJ, Blair EY, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004;57:44-53.
28. Bosch TM, Deenen M, Pruntel R, et al. Screening for polymorphisms in the PXR gene in a Dutch population. Eur J Clin Pharmacol 2006;62:395-9.